Trial Profile
An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy With Tenofovir in HBsAg-positive Patients With Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy (SPEED Study)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Mar 2021
Price :
$35
*
At a glance
- Drugs Tenofovir (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- Acronyms SPEED Study
- 15 Jul 2018 Planned number of patients changed from 6 to 112.
- 15 Jul 2018 Planned End Date changed from 1 Dec 2018 to 1 Mar 2021.
- 15 Jul 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Mar 2021.